Navigation Links
Novavax Reports Second Quarter 2009 Financial Results
Date:8/7/2009

r the remaining 30% of the principal, or $5.1 million. The remaining $5.0 million in outstanding convertible notes matured on July 15, 2009. In accordance with the terms of the notes, the company elected to pay 50% of the principal plus accrued and unpaid interest, or $2.6 million, in cash and issued 1,016,939 shares of common stock to pay the remaining $2.6 million of the principal plus accrued and unpaid interest.
  • Entered into an initial agreement to license the company's Seasonal and Pandemic Influenza VLP technology to ROVI to create a comprehensive influenza vaccine solution including a facility for the Spanish government using our proprietary, recombinant VLP vaccine technology. A non-profit foundation, jointly sponsored by ROVI and the Spanish authorities, will be formed and funded to support Phase III clinical development and other studies necessary to achieve market authorization of the VLP-based influenza vaccines in the European Union, which is targeted for 2012.
  • Raised $21.9 million from the sale of 7.4 million shares of common stock through the ATM program.
  • Launched CPL Biologicals Pvt. Ltd, the previously announced joint venture with Cadila Pharmaceuticals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.
  • Recruited key executives to support the future growth of the company. New appointments include Mr. John Trizzino as Senior Vice President, International and Governmental Affairs, and Mr. Fredrick W. Driscoll as Vice President, Chief Financial Officer and Treasurer.
  • Achieved a major production milestone in the Pandemic H1N1 influenza program by manufacturing a cGMP-quality batch of the company's VLP vaccine candidate against this virus within 11 weeks of receiving the genetic sequence of the pandemic virus strain from the Centers of Disease Control.
  • "Our progress since the first quarter has been transfor
    '/>"/>

    SOURCE Novavax, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
    2. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
    3. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
    4. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
    5. Novavax Announces Repayment of $5 Million of Convertible Debt
    6. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
    7. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
    8. Novavax Appoints Stanley Erck to Board of Directors
    9. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
    10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
    11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. ... immunotherapy company, today announced that the U.S. Food ... Fast Track designation and Phase I clinical trials ... with the mutual co-development agreement signed with Gilead ... Track designation for the DPX-Survivac. , “We have ...
    (Date:2/27/2015)... (PRWEB) February 27, 2015 FamilyFarms Group ... General Manager of State Line Farms, received the 2015 ... a producer, under the age of 35, who has ... is an honor to win the Tomorrow's Top Producer ... who won the Top Producer Award and learning from ...
    (Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
    (Date:2/26/2015)... --  Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, today reported 2014 full year ... objectives, and financial guidance.  Synageva,s management team will ... EST to review the financial results and provide ... call by telephone, please dial (877) 445-4603 for ...
    Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
    ... Foundation (NSF) has awarded the University of Wisconsin-Madison ... $14.8 million over the next six years to continue ... nanoscale. , ,At the nano-scale, materials are so minute ... atom. The UW-Madison researchers' work could have wide-ranging applications ...
    ... I put out the call to DEMOletter readers to raise enough ... victims and volunteers of Hurricane Katrina. I'm delighted to report that ... Houston, and by early this week should be in the hands ... sent to Care for Elders/Sheltering Arms , a program that ...
    ... Wis. -- The WiCell Research Institute's announcement Monday ... million federal contract to create the nation's first National ... the state's pioneering and innovative approach to the new ... continued Wisconsin legislative opposition to embryonic stem cell research, ...
    Cached Biology Technology:UW-Madison gets $14.8 to advance nanoscale research 2UW-Madison gets $14.8 to advance nanoscale research 3UW-Madison gets $14.8 to advance nanoscale research 4Readers respond to Katrina Phone Project 2Readers respond to Katrina Phone Project 3WiCell to host new national stem cell bank 2WiCell to host new national stem cell bank 3WiCell to host new national stem cell bank 4
    (Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
    (Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
    (Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
    Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
    ... the Polytechnic University of Valencia and the University of Oxford ... or cream coloured cup than in a white or red ... senses perceive food in a different way depending on the ... "The colour of the container where food and ...
    ... Sanford-Burnham Medical Research Institute, a nonprofit research ... in the world, and Intrexon Corporation, a leading ... to accelerate stem cell research. Under the agreement, ... selection and gene regulation technologies that are not ...
    ... is available in Spanish . , ... to help livestock producers control stable flies, the most ... An economic impact assessment by scientists ... Unit (AMRU) in Lincoln, Neb., looked at four sectors ...
    Cached Biology News:Cup color influences the taste of hot chocolate 2Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research 2Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research 3Treating stable flies in pastures 2
    ... tested on rat tissue extracts (liver, kidney, spleen, ... cerevisae ) extract. It was also tested with ... lines. Application: A simple and reliable method for ... the detection of the inorganic phosphate released from ...
    ... the leader in electroporation products and specialty ... product line for experiment optimization and large ... a breakthrough in Molecular Delivery. The days ... that typically limited the number of samples ...
    ... 20 System revolutionizes DNA sequencing, delivering sequence ... The Genome Sequencer 20 System includes: ... consumables for library construction, amplification, and sequencing ... novo assembly The instrument ...
    ... RapidVUE is a particle shape and size analyzer ... designed with the utmost simplicity in mind. It ... module and an optical bench. The system is ... easy upgrade for different applications such as dry ...
    Biology Products: